In 2025, the FDA removed 14 peptides from its list of bulk drug substances eligible for compounding, impacting patient access to these therapies in the United States. This resource explains the regulatory background, the peptides affected, reasons for the decision, and considerations for patients…
Under section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies in the United States can prepare medications using bulk drug substances listed by the FDA. These substances do not require individual FDA approval for compounding, provided they meet certain criteria. This regulatory framework allows for customized therapies but depends on the safety and quality of the bulk substances used.
In early 2025, after a review process including public comments and evaluation by the Pharmacy Compounding Advisory Committee, the FDA removed 14 peptides from its bulk drug substances list. This means compounding pharmacies are no longer authorized to produce these peptides without violating FDA regulations. The decision was based on concerns about insufficient human clinical trial data, potential impurities in compounded formulations, and the existence of FDA-approved alternatives for some indications.
The peptides affected include:
The FDA emphasized patient safety as the primary reason. Many of these peptides lack published Phase II or III clinical trial data in humans, making it difficult to confirm their safety and efficacy. For example, BPC-157 has extensive animal research but no advanced human trial data. Additionally, compounding introduces variability in purity, potency, and sterility compared to FDA-approved manufacturing processes, raising concerns about quality control. The FDA also noted that for some therapeutic targets, such as growth hormone deficiency, approved treatments like somatropin are available.
The removal has caused frustration among patients and healthcare providers. Some peptides, like Thymosin alpha-1, have been used internationally with clinical data supporting their use but lack formal FDA approval in the US due to the high cost and complexity of the approval process. Patients relying on these peptides for immune support, tissue repair, or hormone regulation have lost access without an established transition plan.
Growth hormone secretagogues such as CJC-1295, Ipamorelin, and Sermorelin were popular in integrative and anti-aging medicine. While somatropin is FDA-approved, it differs mechanistically and is more expensive, leading some patients to prefer secretagogues that stimulate endogenous hormone production.
Professional groups representing compounding pharmacies have challenged the FDA's decision, arguing that clinical experience and supervised use should be considered alongside formal trial data.
Patients receiving these peptides through compounding pharmacies should consult their healthcare providers before making any changes. Abrupt discontinuation is not advised, especially for growth hormone secretagogues, which may require gradual tapering. Providers may discuss FDA-approved alternatives or other therapeutic strategies based on individual needs.
Some peptides, such as GHK-Cu, remain available in topical cosmetic products, which are regulated differently from injectable compounded drugs.
This regulatory change reflects a broader FDA trend toward stricter oversight of compounded medications, as seen previously with GLP-1 receptor agonists. It highlights the challenge in the US regulatory system of balancing patient access to promising compounds with the need for rigorous safety and efficacy data.
The reclassification may encourage pharmaceutical companies or research institutions to initiate formal clinical trials for some peptides, potentially leading to FDA approval in the future. BPC-157 is one candidate discussed for such development due to its extensive preclinical data.
, -
Disclaimer: This resource is for informational purposes only and does not constitute medical advice. The regulatory status of peptides may change. Always consult a qualified healthcare professional before starting, stopping, or modifying peptide treatments.